secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039797
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q2 net loss $71.1M; IND cleared for ATA3219; tab-cel BLA meeting scheduled
--------------------------------------------------------------------------------

- Net loss of $71.1M ($0.68 per share) vs net income of $18.5M ($0.18) in Q2 2022, which included one-time gains.
- Cash, equivalents and investments $153.6M as of June 30, 2023; expected runway into Q2 2024 (net cash used in ops $52.8M in Q2).
- IND cleared for allogeneic CAR T ATA3219 in relapsed/refractory B-cell NHL; Phase 1 to start in coming months.
- FDA meeting scheduled to resolve comparability for tab-cel (EBVALLO) BLA submission; commercial discussions advancing.
- Primary analysis of ATA188 Phase 2 EMBOLD study in progressive MS to be communicated in early November with data from >90 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023039797/0000950170-23-039797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023039797/atra-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer